Fig. 1: Schematic illustration of the antitumor immunity induced by the inhalation of mscFv/siPD-L1@LNP.
From: Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA
Lung tumor-bearing mice are administered LNP co-delivering mscFv and siPD-L1 via inhalation. Following the internalization of LNP by cancer cells, mscFv and siPD-L1 are simultaneously released, translating into anti-DDR1 scFv and knocking down PD-L1 expression, respectively. The secreted anti-DDR1 scFv binds to DDR1 ECD, blocking its interaction with collagen, which disrupts collagen fiber alignment and reduces tumor stiffness. This creates a tumor microenvironment more favorable for immune effector cell infiltration. Consequently, antitumor immunity is enhanced by overcoming both the physical and immune barriers of the tumor’s defense mechanisms.
